Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-thymocyte globulin + dexamethasone + etoposide
- Development stage
- Unknown
- Lead developer
- Cincinnati Children's Hospital Medical Center
- Modality
- Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of anti-thymocyte globulin (ATG), dexamethasone, and etoposide is a chemo-immunotherapy regimen known as Hybrid ImmunoTherapy (HIT-HLH). Developed and studied by the Children's Hospital Medical Center, Cincinnati, this regimen is designed as an induction therapy for pediatric patients with hemophagocytic lymphohistiocytosis (HLH). It represents a "hybrid" approach that integrates the T-cell depleting effects of rabbit ATG (traditionally used in European protocols) with the cytotoxic backbone of etoposide and dexamethasone (the international HLH-94/2004 standard). The regimen aims to rapidly control the life-threatening hyperinflammation characteristic of HLH by targeting multiple immune pathways, including the depletion of activated T-lymphocytes and the inhibition of cytokine production.
- Brand names
- Thymoglobulin
- Other names
- Hybrid ImmunoTherapyATG/Dexamethasone/EtoposideATG + dexamethasone + etoposide
02
Targets
GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on anti-thymocyte globulin + dexamethasone + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-thymocyte globulin + dexamethasone + etoposide.